Top-News
Pharmazeutika Großbritannien

AstraZeneca plc ADR News

Aktie
WKN:  886715 ISIN:  US0463531089 US-Symbol:  AZN
70,50 €
-0,50 €
-0,70%
16.05.24 17:28:02
Handeln Depot/Watchlist
Aktienanzahl *
3,10 Mrd.
Marktkapitalisierung *
219,77 Mrd. €
Streubesitz
-
Faktor
1
Originalaktie
GB0009895292
Index-Zugehörigkeit
Nasdaq 100
IR-Website
zur Website
*Stand: 06.03.2024

AstraZeneca plc ADR News

25.04.24 - PR Newswire
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
26.02.24 - PR Newswire
Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign
Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign Canada NewsWire
07.02.24 - PR Newswire
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain PR Newswire
07.02.24 - PR Newswire
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain PR Newswire
08.01.24 - PR Newswire
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer PR Newswire
02.01.24 - PR Newswire
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-​Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca PR Newswire
02.01.24 - PR Newswire
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-​Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca PR Newswire
19.12.23 - PR Newswire
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer PR Newswire
30.11.23 - PR Newswire
Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology
Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-​Oncology Drug Combinations with CIVO® Technology PR Newswire
10.11.23 - ARIVA.DE Redaktion
Nasdaq 100 zur Stunde 2,02 Prozent mehr (15.495 Pkt.)
Die Aktie von KLA-​Tencor ist derzeit der größte Gewinner im Nasdaq 100-Index. Der Index steigt stark um 2,02 Prozent.
10.11.23 - ARIVA.DE Redaktion
0,68 Prozent Plus: Nasdaq 100 legt etwas zu (15.290 Pkt.)
Für den Nasdaq 100-Index verlief der bisherige Aktienhandel heute positiv. Das Börsenbarometer steigt kräftig um 0,68 Prozent.
20.10.23 - PR Newswire
Thinking about trading options or stock in NVIDIA, CVS Health, PayPal Holdings, AstraZeneca, or BP?
Thinking about trading options or stock in NVIDIA, CVS Health, PayPal Holdings, AstraZeneca, or BP? PR Newswire
18.10.23 - ARIVA.DE Redaktion
1,28 Prozent Minus: Nasdaq 100 tendiert leichter (14.928 Pkt.)
Für den Nasdaq 100-Index brachte der bisherige Aktienhandel heute leichte Verluste. Das Börsenbarometer rutscht um 1,28 Prozent ab.
18.10.23 - ARIVA.DE Redaktion
Nasdaq 100 gibt leicht nach: 154 Punkte verloren (14.968 Pkt.)
Für den Nasdaq 100-Index brachte der bisherige Aktienhandel heute leichte Verluste. Das Börsenbarometer sinkt leicht um 1,02 Prozent.
18.10.23 - ARIVA.DE Redaktion
Nasdaq 100 heute kaum bewegt (15.090 Pkt.)
Kurs­verluste und Kursgewinn halten sich beim Nasdaq 100 gegenwärtig in etwa die Waage. Derzeit liegt das Kursbarometer mit 0,21 Prozent ganz leicht im Minus.
18.10.23 - PR Newswire
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care PR ...
18.10.23 - PR Newswire
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care PR ...
13.10.23 - PR Newswire
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review PR Newswire
13.10.23 - PR Newswire
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review PR Newswire
12.10.23 - PR Newswire
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers PR Newswire

Newssuche

Videos

newspaper
08:55 Uhr -3,55%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »